This is a first analysis on documented cases of the LEOSS study on the epidemiology of SARS-CoV‑2.
More than 20 research teams working on comprehensive analyses using the LEOSS data. A public data set is now available. All scientists are invited to register to get access to the more extensive scientific data set.
Note, in the following diagrams, we present descriptive analysis. This means, in the graphs, the distribution of values is pictured for each clinical phase separately. The data of one patient is e.g. included in the distribution for the uncomplicated phase AND the complicated phase. A cause-effect analysis is not yet performed.
With a click on each image you can open a larger version.
Study Population
Definition of Clinical Phases & Distribution at Diagnosis
Uncomplicated Phase
asymtomatic
OR
symptoms of upper respiratory tract infection
nausea, emesis, diarrhea
fever
Complicated Phase
need for new oxygen supplementation
clinically meaningful increase of prior oxygen home therapy
PaO2 at room air < 70 mmHg
SO2 at room air < 90 %
AST or ALT > 5x ULN
new cardiac arrhythmia
new pericardial effusion > 1 cm
new heart failure with pulmonary edema, congestive hepatopathy or peripheral edema
Critical Phase
need for catecholamines
life-threatening cardiac arrhythmia
need for unplanned mechanical ventilation (invasive or non-invasive)
prolongation (>24h) of planned mechanical ventilation
Liver failure with Quick < 50 % or INR > 3.5
qSOFA >= 2
acute renal failure in need of dialysis
Recovery Phase*
improvement by one degree of severity according to this scheme or discharge from hospital
AND
defervescence
AND
no further progression or re-hospitalization
* Recovery phase in outpatient settings can be achieved by uncomplicated patients after 14 days of observation without disease progression.
Comorbidities
Liver Enzymes
Cardiac Markers
Inflammatory Markers
